Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 4

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
. The Company bases this estimate on
an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License
Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned
by the Company.

Research
and Development Cost

Research
and development (R& D) costs are expensed as incurred. R& D costs are related to the Company’s internally funded development
of the Company’s product developments and patents. The Company R& D costs were $ 0 32,500

Fair
Value Measurement

The
estimated fair values of financial instruments reported in the consolidated financial statements have been determined using available
market information and valuation methodologies, as applicable. The fair value of cash due to its short maturity is classified as a Level
1 instrument within the fair value hierarchy.

Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Entities are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value
based upon the following fair value hierarchy:

  Level      Quoted                                                                                                                               
  Level      Observable                                                                                                                           
  Level      Unobservable                                                                                                                         

As
of June 30, 2025, the following table represents the Company’s fair value hierarchy for items that are required to be measured
at fair value on a recurring basis:

SCHEDULE
OF FAIR VALUE HIERARCHY MEASURED AT RECURRING BASIS

                                  Level      Level        Level  
                                  1          2                3  
  Investment                                            $17,733  
  Securities (Related Party)                                     
 ─────────────────────────────────────────────────────────────────

As
of September 30, 2024, the following table represents the Company’s fair value hierarchy for items that are required to be measured
at fair value on a recurring basis:

                                  Level      Level        Level  
                                  1          2                3  
  Investment                                            $17,733  
  Securities (Related Party)                                     
 ─────────────────────────────────────────────────────────────────

Stock-Based
Compensation

The
Company accounts for share-based compensation in accordance with the fair value recognition provisions of FASB ASC Topic 718, Share-based
Payment, which requires all share-based payments to employees,